CUBE vs NBIX · P/E 25, rev $1.07B vs P/E 45, rev $2.36B
CubeSmart (CUBE) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the CUBE and NBIX stock pages for the full models.
Not investment advice.